SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-017209
Filing Date
2024-04-30
Accepted
2024-04-30 15:26:51
Documents
15
Period of Report
2024-04-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38777
2 ex10-1.htm EX-10.1 27473
  Complete submission text file 0001493152-24-017209.txt   244633

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gtbp-20240425.xsd EX-101.SCH 3024
4 XBRL LABEL FILE gtbp-20240425_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE gtbp-20240425_pre.xml EX-101.PRE 22365
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3671
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 24896715
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)